Association of Mal/TIRAP S180L variant polymorphism with decreased infection risk in patients with advanced HIV-1 infection

Cytokine

Volumn 60, Issue 1, 2012, Pages 104-107

  Papadopoulos, Antonios I ^a   Ferwerda, Bart ^b   Antoniadou, Anastasia ^a   Sakka, Vissaria ^a   Galani, Lambrini ^a   Kavatha, Dimitra ^a   Panagopoulos, Periklis ^a   Poulakou, Garyphalia ^a   Protopapas, Konstantinos ^a   van der Meer, Jos W M ^b   Netea, Mihai G ^b   Giamarellos Bourboulis, Evangelos J ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adapter proteins; HIV infection; Infection risk; Mal polymorphisms

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GREECE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MY88D ADAPTOR LIKE PROTEIN GENE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-1; RISK FACTORS; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865410348     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.008     Document Type: Article

References (29)

1. Cadogan M., Dalgleish A.G. HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis 2008, 8:675-684.
2. Lane H.C. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010, 18:2-6.
3. Takeda K., Akira S. Toll receptors and pathogen resistance. Cell Microbiol 2003, 5:143-153.
4. Abbas A.K., Lichtman A.H., Pillai S. Cellular and molecular immunology 2010, Saunders Elsevier, Philadelphia. 6th ed.
5. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
6. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
7. Kenny E.F., O'Neill L.A. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008, 43:342-349.
8. O'Neill L.A., Fitzgerald K.A., Bowie A.G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003, 24:286-290.
9. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-263.
10. Kawai T., Akira S. TLR signalling. Cell Death Differ 2006, 13:816-825.
11. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A., Mausell A.S., Brady G., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001, 413:78-83.
12. Papadopoulos A.I., Ferwerda B., Antoniadou A., Sakka V., Galani L., Kavatha D., et al. Association of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms with increased infection risk in patients with advanced HIV-1 infection. Clin Infect Dis 2010, 51:242-247.
13. Dissanayeke S.R., Levin S., Pienaar S., Wood K., Eley B., Beatty D., et al. Polymorphic variation in TIRAP is not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some ethnic groups. PLoS ONE 2009, 4:e6698.
14. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007, 39:523-528.
15. Castiblanco J., Varela D.C., Castaño-Rodríguez N., Rojas-Villarraga A., Hincapié M.E., Anaya J.M. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008, 8:541-544.
16. Ferwerda B., Alonso S., Banahan K., McCall M.B., Giamarellos-Bourboulis E.J., Ramakers B.P., et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci USA 2009, 106:10272-10277.
17. Ramasawmy R., Cunha-Neto E., Fae K.C., Borba S.C., Teixeira P.C., Ferreira S.C., et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy. J Infect Dis 2009, 199:1838-1845.
18. Selvaraj P., Harishankar M., Singh B., Jawahar M.S., Banurekha V.V. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis (Edinb) 2010, 90:306-310.
19. Greene J.A., Moormann A.M., Vulule J., Bockarie M.J., Zimmerman P.A., Kazura J.W. Toll-like receptor polymorphisms in malaria-endemic populations. Malar J 2009, 8:50.
20. Nejentsev S., Thye T., Szeszko J.S., Stevens H., Balabanova Y., Chinbuah A.M., et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet 2008, 40:261-262.
21. Hawn T.R., Dunstan S.J., Thwaites G.E., Simmons C.P., Thuong N.T., Lan N.T., et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006, 194:1127-1134.
22. Kumpf O., Giamarellos-Bourboulis E.J., Koch A., Hamann L., Mouktaroudi M., Oh D.Y., et al. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care 2010, 14:R103.
23. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993, 341:441.
24. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41(RR-17):1-19.
25. Christ-Crain M., Stolz D., Bingisser R., Müller C., Miedinger D., Huber P.R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
26. Seage G.R., Losina E., Goldie S.J., Paltiel A.D., Kimmel A.D., Freedberg K.A. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002, 30:421-438.
27. Sheedy F.J., O'Neill L.A. The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signalling. J Leukoc Biol 2007, 82:196-203.
28. Mogensen T.H., Melchjorsen J., Larsen C.S., Paludan S.R. Innate immune recognition and activation during HIV infection. Retrovirology 2010, 7:54.
29. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.